<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121133/" ref="ordinalpos=24&amp;ncbi_uid=6465247&amp;link_uid=PMC4121133" image-link="/pmc/articles/PMC4121133/figure/pone-0103551-g004/" class="imagepopup">Figure 4. Summary of colorectal cancer (CRC) sub-classifications based on their <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> profiles..  From: Activated cMET and IGF1R-Driven PI3K <span class="highlight" style="background-color:">Signaling</span> Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status. </a></div><br /><div class="p4l_captionBody">Schematic summarizing the sub-classification of CRCs based on their signaling pathway profiles and KRAS mutational status. The possible therapeutic options for each sub-class based on their pathway profiles are indicated.</div></div>